董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Allan J. Camaisa | 男 | Director | 66 | 98.27万美元 | 10.53 | 2026-03-20 |
| Scott Leftwich | 男 | Independent Director | 65 | 12.21万美元 | 29.26 | 2026-03-20 |
| Eric Poma | 男 | Chief Executive Officer and Director | 54 | 67.39万美元 | 6.51 | 2026-03-20 |
| James Schoeneck | 男 | Chairman of the Board and Independent Director | 68 | 16.30万美元 | 18.81 | 2026-03-20 |
| Alan Stewart | 男 | Independent Director | 62 | 12.71万美元 | 1.39 | 2026-03-20 |
| George Peoples | 男 | Independent Director | 64 | 11.46万美元 | 1.14 | 2026-03-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Jackson | 男 | Chief Financial Officer and Corporate Secretary | 57 | 59.40万美元 | 0.66 | 2026-03-20 |
| Eric Poma | 男 | Chief Executive Officer and Director | 54 | 67.39万美元 | 6.51 | 2026-03-20 |
| Antonio F. Santidrian | 男 | Chief Scientific Officer and Head of Technical Operations | 48 | 57.70万美元 | 0.36 | 2026-03-20 |
董事简历
中英对照 | 中文 | 英文- Allan J. Camaisa
-
Allan Camaisa目前的主要职业是CALIDI BIOTHERAPEUTICS，INC.的首席执行官、总裁和董事会主席。Camaisa先生是美国公民。
Allan J. Camaisa has been a director of Calidi since February 2018 and resigned as the Chairman and Chief Executive Officer of the Company effective April 21, 2025. Mr. Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills in bootstrapping startups. His accomplishments include four successful exits sold to publicly traded Fortune 1000 companies, authorship of seven US patents, and an Ernst & Young Entrepreneur of the Year award. Mr. Camaisa was previously a director of snaploT, Inc., a self service enabled clinical platform designed to create, launch, and manage clinical trials from January 2013 to September 2020. From August 2014 to May 2017, Mr. Camaisa was the CEO and Chairman of Parallel 6, Inc., a digital mobile/cloud software platform for managing pharmaceutical patient clinical trials. In 2005, Mr. Camaisa founded Anakam, Inc., a software security company for managing digital access to medical records, and also served as Anakam's Chief Executive Officer from January 2005 to October 2010. Before beginning his career in business, Mr. Camaisa served eight years as a surface warfare officer in the US Navy. He graduated from the United States Naval Academy with a B.S. in Engineering, and also completed the Owner/President Management program at Harvard Business School. - Allan Camaisa目前的主要职业是CALIDI BIOTHERAPEUTICS，INC.的首席执行官、总裁和董事会主席。Camaisa先生是美国公民。
- Allan J. Camaisa has been a director of Calidi since February 2018 and resigned as the Chairman and Chief Executive Officer of the Company effective April 21, 2025. Mr. Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills in bootstrapping startups. His accomplishments include four successful exits sold to publicly traded Fortune 1000 companies, authorship of seven US patents, and an Ernst & Young Entrepreneur of the Year award. Mr. Camaisa was previously a director of snaploT, Inc., a self service enabled clinical platform designed to create, launch, and manage clinical trials from January 2013 to September 2020. From August 2014 to May 2017, Mr. Camaisa was the CEO and Chairman of Parallel 6, Inc., a digital mobile/cloud software platform for managing pharmaceutical patient clinical trials. In 2005, Mr. Camaisa founded Anakam, Inc., a software security company for managing digital access to medical records, and also served as Anakam's Chief Executive Officer from January 2005 to October 2010. Before beginning his career in business, Mr. Camaisa served eight years as a surface warfare officer in the US Navy. He graduated from the United States Naval Academy with a B.S. in Engineering, and also completed the Owner/President Management program at Harvard Business School.
- Scott Leftwich
-
Scott Leftwich目前的主要职业是SECBL的管理成员，同时也是CALIDI BIOTHERAPEUTICS，INC.的董事。Leftwich先生是美国公民。
Scott Leftwich was an early investor and has been a director of Calidi since May 2019. In addition, since 2017 Mr. Leftwich has been an investor and member of the Board of Advisors at Skopos Labs, Inc. Mr. Leftwich's experience includes serving in various executive positions in private companies, overseeing substantial growth and liquidity events with Fortune 1000 companies. From December 2011 to April 2016, Mr. Leftwich was the CEO and General Manager at InterMedHx, LLC, a healthcare software company, which was acquired by Cerner Corporation in 2014. From September 2005 to December 2011, he was the COO and general manager at Anakam, Inc., a security software company focused on the protection of personal healthcare information within patient facing portals. Anakam was acquired by Equifax (NYSE: EFX) in 2010. Mr. Leftwich is also a retired Naval officer who served as a P 3 pilot in the Navy and retired with the rank of Commander. Mr. Leftwich holds an MBA (with honors) from Harvard Business School, in addition to a B.S. (with distinction) from the US Naval Academy. - Scott Leftwich目前的主要职业是SECBL的管理成员，同时也是CALIDI BIOTHERAPEUTICS，INC.的董事。Leftwich先生是美国公民。
- Scott Leftwich was an early investor and has been a director of Calidi since May 2019. In addition, since 2017 Mr. Leftwich has been an investor and member of the Board of Advisors at Skopos Labs, Inc. Mr. Leftwich's experience includes serving in various executive positions in private companies, overseeing substantial growth and liquidity events with Fortune 1000 companies. From December 2011 to April 2016, Mr. Leftwich was the CEO and General Manager at InterMedHx, LLC, a healthcare software company, which was acquired by Cerner Corporation in 2014. From September 2005 to December 2011, he was the COO and general manager at Anakam, Inc., a security software company focused on the protection of personal healthcare information within patient facing portals. Anakam was acquired by Equifax (NYSE: EFX) in 2010. Mr. Leftwich is also a retired Naval officer who served as a P 3 pilot in the Navy and retired with the rank of Commander. Mr. Leftwich holds an MBA (with honors) from Harvard Business School, in addition to a B.S. (with distinction) from the US Naval Academy.
- Eric Poma
-
Eric Poma，被任命为Calidi的首席执行官和董事，自2025年4月22日起生效。最近，Poma博士于2009年2月至2025年1月在临床阶段的生物技术公司Molecular Templates（纳斯达克股票代码：MTEM）担任首席执行官和董事会成员。2005年3月至2008年9月，Poma博士担任Innovive Pharmaceuticals业务发展副总裁。2001年至2005年，Poma博士在Imclone Systems，Inc.担任多个高级职位。2000年至2001年，Poma博士在Eagle Growth Investors，LLC担任分析师。Poma博士在北卡罗来纳大学教堂山分校获得微生物学和免疫学博士学位，在Leonard N. Stern商学院获得工商管理硕士学位，在北卡罗来纳大学教堂山分校获得生物学理学学士学位。
Eric Poma was appointed as the Chief Executive Officer and director of Calidi effective April 22, 2025. Most recently, Dr. Poma served as CEO and as a member of the board of directors at Molecular Templates (NASDAQ: MTEM), a clinical stage biotechnology company, from February 2009 until January 2025. From March 2005 to September 2008, Dr. Poma served as Vice President, Business Development of Innovive Pharmaceuticals. From 2001 to 2005, Dr. Poma held various senior level positions at Imclone Systems, Inc. From 2000 to 2001 Dr. Poma served as an analyst at Eagle Growth Investors, LLC. Dr. Poma received a Ph.D. in Microbiology and Immunology from University of North Carolina at Chapel Hill, an M.B.A. from Leonard N. Stern School of Business and a Bachelor of Science in Biology from University of North Carolina at Chapel Hill. - Eric Poma，被任命为Calidi的首席执行官和董事，自2025年4月22日起生效。最近，Poma博士于2009年2月至2025年1月在临床阶段的生物技术公司Molecular Templates（纳斯达克股票代码：MTEM）担任首席执行官和董事会成员。2005年3月至2008年9月，Poma博士担任Innovive Pharmaceuticals业务发展副总裁。2001年至2005年，Poma博士在Imclone Systems，Inc.担任多个高级职位。2000年至2001年，Poma博士在Eagle Growth Investors，LLC担任分析师。Poma博士在北卡罗来纳大学教堂山分校获得微生物学和免疫学博士学位，在Leonard N. Stern商学院获得工商管理硕士学位，在北卡罗来纳大学教堂山分校获得生物学理学学士学位。
- Eric Poma was appointed as the Chief Executive Officer and director of Calidi effective April 22, 2025. Most recently, Dr. Poma served as CEO and as a member of the board of directors at Molecular Templates (NASDAQ: MTEM), a clinical stage biotechnology company, from February 2009 until January 2025. From March 2005 to September 2008, Dr. Poma served as Vice President, Business Development of Innovive Pharmaceuticals. From 2001 to 2005, Dr. Poma held various senior level positions at Imclone Systems, Inc. From 2000 to 2001 Dr. Poma served as an analyst at Eagle Growth Investors, LLC. Dr. Poma received a Ph.D. in Microbiology and Immunology from University of North Carolina at Chapel Hill, an M.B.A. from Leonard N. Stern School of Business and a Bachelor of Science in Biology from University of North Carolina at Chapel Hill.
- James Schoeneck
-
James Schoeneck，自2020年7月起担任Calidi的董事。Schoeneck先生目前还自2010年4月起担任Fibrogen Inc（纳斯达克：FGEN）的成员和董事会主席，此前还曾于2019年1月至2020年2月担任该公司的临时首席执行官。从2015年11月到2018年3月，Schoeneck先生是Anaptysbio，Inc（纳斯达克：ANAB）的董事，该公司是一家用于重症疾病的治疗性抗体开发公司。他曾于2007年担任Depomed，Inc.董事会董事，并于2011年4月至2017年3月期间担任该公司总裁兼首席执行官，领导Depomed转型为一家商业专业制药公司。2005年至2011年，他担任私营生物制药公司BrainCells Inc的首席执行官。Schoeneck先生丰富的生物技术经验还包括2003年至2004年担任处于发展阶段的生物技术公司ActivX BioSciences，Inc.的首席执行官，1999年至2003年担任制药和诊断产品公司Prometheus Laboratories Inc的总裁兼首席执行官三年，以及1996年至1999年担任Centocor Inc（现为Janssen Biotech，Inc.）的副总裁、商业和免疫学总经理三年。Schoeneck先生拥有杰克逊维尔州立大学教育学学士学位。Schoeneck先生完全有资格担任Calidi Biotherapeutics，Inc.董事，基于上述资格、他的执行管理领导能力以及他在生物技术和制药行业的丰富经验。
James Schoeneck has been a director of Calidi since July 2020, he was appointed as the Chairman of the Board effective April 22, 2025. Mr. Schoeneck is also currently a member and Chairman of the Board at Fibrogen Inc (Nasdaq: FGEN) since April 2010, and also previously served as its Interim CEO from January 2019 to February 2020. From November 2015 to March 2018, Mr. Schoeneck was a director of Anaptysbio, Inc (Nasdaq: ANAB), a therapeutic antibody development company for severe disease. He was previous a director of the Board of Depomed, Inc. in 2007, and also served as its President and CEO from April, 2011 to March, 2017, and led Depomed's transformation into a commercial specialty pharmaceutical company. From 2005 until 2011, he was CEO of BrainCells Inc, a privately held biopharmaceutical company. Mr. Schoeneck's diverse biotech experience further includes serving as CEO of ActivX BioSciences, Inc., a development stage biotechnology company from 2003 to 2004, three years as President and CEO of Prometheus Laboratories Inc, a pharmaceutical and diagnostics product company, from 1999 to 2003, as well as three years from 1996 to 1999 as Vice President, Commercial and General Manager, Immunology, at Centocor Inc (now Janssen Biotech, Inc.). Mr. Schoeneck holds a B.S. in Education from Jacksonville State University. - James Schoeneck，自2020年7月起担任Calidi的董事。Schoeneck先生目前还自2010年4月起担任Fibrogen Inc（纳斯达克：FGEN）的成员和董事会主席，此前还曾于2019年1月至2020年2月担任该公司的临时首席执行官。从2015年11月到2018年3月，Schoeneck先生是Anaptysbio，Inc（纳斯达克：ANAB）的董事，该公司是一家用于重症疾病的治疗性抗体开发公司。他曾于2007年担任Depomed，Inc.董事会董事，并于2011年4月至2017年3月期间担任该公司总裁兼首席执行官，领导Depomed转型为一家商业专业制药公司。2005年至2011年，他担任私营生物制药公司BrainCells Inc的首席执行官。Schoeneck先生丰富的生物技术经验还包括2003年至2004年担任处于发展阶段的生物技术公司ActivX BioSciences，Inc.的首席执行官，1999年至2003年担任制药和诊断产品公司Prometheus Laboratories Inc的总裁兼首席执行官三年，以及1996年至1999年担任Centocor Inc（现为Janssen Biotech，Inc.）的副总裁、商业和免疫学总经理三年。Schoeneck先生拥有杰克逊维尔州立大学教育学学士学位。Schoeneck先生完全有资格担任Calidi Biotherapeutics，Inc.董事，基于上述资格、他的执行管理领导能力以及他在生物技术和制药行业的丰富经验。
- James Schoeneck has been a director of Calidi since July 2020, he was appointed as the Chairman of the Board effective April 22, 2025. Mr. Schoeneck is also currently a member and Chairman of the Board at Fibrogen Inc (Nasdaq: FGEN) since April 2010, and also previously served as its Interim CEO from January 2019 to February 2020. From November 2015 to March 2018, Mr. Schoeneck was a director of Anaptysbio, Inc (Nasdaq: ANAB), a therapeutic antibody development company for severe disease. He was previous a director of the Board of Depomed, Inc. in 2007, and also served as its President and CEO from April, 2011 to March, 2017, and led Depomed's transformation into a commercial specialty pharmaceutical company. From 2005 until 2011, he was CEO of BrainCells Inc, a privately held biopharmaceutical company. Mr. Schoeneck's diverse biotech experience further includes serving as CEO of ActivX BioSciences, Inc., a development stage biotechnology company from 2003 to 2004, three years as President and CEO of Prometheus Laboratories Inc, a pharmaceutical and diagnostics product company, from 1999 to 2003, as well as three years from 1996 to 1999 as Vice President, Commercial and General Manager, Immunology, at Centocor Inc (now Janssen Biotech, Inc.). Mr. Schoeneck holds a B.S. in Education from Jacksonville State University.
- Alan Stewart
-
Alan Stewart，自2023年10月10日起担任Calidi的董事。Stewart先生作为财务主管和董事会成员拥有丰富的经验，在多个行业拥有良好的业绩记录。现任SoundThinking，Inc.（一家上市SaaS软件公司，专注于广域声学枪声检测）的首席财务官。自任职以来，他已成功带领公司在纳斯达克市场首次公开发行股票，促进了显着增长，并完成了对技术提供商的收购。斯图尔特此前担任的职务包括担任Fit Advisors，LLC的总裁，在那里他成功地发起了一家咨询公司，并在各个行业完成了大量并购交易。他还曾在RA Capital Advisors，LLC担任董事总经理，专门从事并购和融资交易。Stewart先生拥有强大的教育背景，拥有哈佛商学院金融硕士学位和美国海军学院卓越的海洋学理学学士学位。他曾担任FINRA授权代理，拥有Series 63和Series 79证书（非活动）。
Alan Stewart has been a director of Calidi since October 10, 2023. Mr. Stewart has extensive experience as a financial executive and board member with a proven track record in diverse industries. He is currently the Chief Financial Officer of Soundthinking, Inc., a publicly traded SaaS software company specializing in wide area acoustic gunshot detection. Since his appointment, he has successfully led the company through an IPO on the Nasdaq market, facilitated significant growth, and completed acquisitions of technology providers. Mr. Stewart's prior roles include serving as President of Fit Advisors, LLC, where he launched a successful consultancy and completed numerous M&A transactions in various industries. He also served as a Managing Director at RA Capital Advisors, LLC, specializing in M&A and financing transactions. Mr. Stewart has a strong educational background, holding an M.B.A. in Finance from Harvard Business School and a Bachelor of Science with Distinction in Oceanography from the United States Naval Academy. He has served as a FINRA Licensed Agent with Series 63 and Series 79 credentials (Inactive). - Alan Stewart，自2023年10月10日起担任Calidi的董事。Stewart先生作为财务主管和董事会成员拥有丰富的经验，在多个行业拥有良好的业绩记录。现任SoundThinking，Inc.（一家上市SaaS软件公司，专注于广域声学枪声检测）的首席财务官。自任职以来，他已成功带领公司在纳斯达克市场首次公开发行股票，促进了显着增长，并完成了对技术提供商的收购。斯图尔特此前担任的职务包括担任Fit Advisors，LLC的总裁，在那里他成功地发起了一家咨询公司，并在各个行业完成了大量并购交易。他还曾在RA Capital Advisors，LLC担任董事总经理，专门从事并购和融资交易。Stewart先生拥有强大的教育背景，拥有哈佛商学院金融硕士学位和美国海军学院卓越的海洋学理学学士学位。他曾担任FINRA授权代理，拥有Series 63和Series 79证书（非活动）。
- Alan Stewart has been a director of Calidi since October 10, 2023. Mr. Stewart has extensive experience as a financial executive and board member with a proven track record in diverse industries. He is currently the Chief Financial Officer of Soundthinking, Inc., a publicly traded SaaS software company specializing in wide area acoustic gunshot detection. Since his appointment, he has successfully led the company through an IPO on the Nasdaq market, facilitated significant growth, and completed acquisitions of technology providers. Mr. Stewart's prior roles include serving as President of Fit Advisors, LLC, where he launched a successful consultancy and completed numerous M&A transactions in various industries. He also served as a Managing Director at RA Capital Advisors, LLC, specializing in M&A and financing transactions. Mr. Stewart has a strong educational background, holding an M.B.A. in Finance from Harvard Business School and a Bachelor of Science with Distinction in Oceanography from the United States Naval Academy. He has served as a FINRA Licensed Agent with Series 63 and Series 79 credentials (Inactive).
- George Peoples
-
George Peoples，自2024年7月1日起担任Calidi的董事。Peoples博士作为一名外科医生和研究科学家在军队服役30年。Peoples博士目前是统一服务大学Health Sciences（USUHS）的外科教授和MD安德森癌症中心（MDACC）的外科肿瘤学教授（兼职）。此外，Peoples博士还是Cancer Insight的创始人和首席执行官，以及癌症疫苗开发计划的创始人和董事。他目前还自2019年起担任德克萨斯生物医学研究所的董事会成员，并自2017年起担任圣安东尼奥医学基金会的受托人。Peoples博士毕业于美国军事学院、西点军校和约翰霍普金斯医学院。他在哈佛布莱根妇女医院完成了外科训练，还在哈佛医学院生物癌症治疗实验室完成了博士后研究金。随后，他在MDACC完成了外科肿瘤学研究金，之后成为WRAMC外科肿瘤学主任。他发表了300多篇关于免疫肿瘤学和癌症疫苗开发的同行评审手稿、摘要和书籍章节。Peoples博士于1988年获得约翰霍普金斯大学医学院的医学博士学位，并于1984年获得美国军事学院的理学学士学位。
George Peoples was appointed as a director of Calidi effective July 1, 2024. Dr. Peoples served 30 years of active duty as a surgeon and research scientist in the military. Dr. Peoples is currently a Professor of Surgery at Uniformed Services University of the Health Sciences (USUHS) and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). In addition, Dr. Peoples is also the Founder and CEO of Cancer Insight, and the Founder and a director of the Cancer Vaccine Development Program. He also currently serves as a Board Member for Texas Biomedical Research Institute since 2019 and as a Trustee for San Antonio Medical Foundation since 2017. Dr. Peoples is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard's Brigham and Women's Hospital and also completed a postdoctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC prior to becoming the Chief of Surgical Oncology at WRAMC. He has published over 300 peer reviewed manuscripts, abstracts, and book chapters on immuno oncology and cancer vaccine development. Dr. Peoples received his M.D. from Johns Hopkins University School of Medicine in 1988 and his Bachelor of Science from the United States Military Academy in 1984. - George Peoples，自2024年7月1日起担任Calidi的董事。Peoples博士作为一名外科医生和研究科学家在军队服役30年。Peoples博士目前是统一服务大学Health Sciences（USUHS）的外科教授和MD安德森癌症中心（MDACC）的外科肿瘤学教授（兼职）。此外，Peoples博士还是Cancer Insight的创始人和首席执行官，以及癌症疫苗开发计划的创始人和董事。他目前还自2019年起担任德克萨斯生物医学研究所的董事会成员，并自2017年起担任圣安东尼奥医学基金会的受托人。Peoples博士毕业于美国军事学院、西点军校和约翰霍普金斯医学院。他在哈佛布莱根妇女医院完成了外科训练，还在哈佛医学院生物癌症治疗实验室完成了博士后研究金。随后，他在MDACC完成了外科肿瘤学研究金，之后成为WRAMC外科肿瘤学主任。他发表了300多篇关于免疫肿瘤学和癌症疫苗开发的同行评审手稿、摘要和书籍章节。Peoples博士于1988年获得约翰霍普金斯大学医学院的医学博士学位，并于1984年获得美国军事学院的理学学士学位。
- George Peoples was appointed as a director of Calidi effective July 1, 2024. Dr. Peoples served 30 years of active duty as a surgeon and research scientist in the military. Dr. Peoples is currently a Professor of Surgery at Uniformed Services University of the Health Sciences (USUHS) and a Professor (adjunct) of Surgical Oncology at MD Anderson Cancer Center (MDACC). In addition, Dr. Peoples is also the Founder and CEO of Cancer Insight, and the Founder and a director of the Cancer Vaccine Development Program. He also currently serves as a Board Member for Texas Biomedical Research Institute since 2019 and as a Trustee for San Antonio Medical Foundation since 2017. Dr. Peoples is a graduate of the United States Military Academy, West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard's Brigham and Women's Hospital and also completed a postdoctoral fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School. He then completed a surgical oncology fellowship at MDACC prior to becoming the Chief of Surgical Oncology at WRAMC. He has published over 300 peer reviewed manuscripts, abstracts, and book chapters on immuno oncology and cancer vaccine development. Dr. Peoples received his M.D. from Johns Hopkins University School of Medicine in 1988 and his Bachelor of Science from the United States Military Academy in 1984.
高管简历
中英对照 | 中文 | 英文- Andrew Jackson
Andrew Jackson，自2022年5月起担任Eterna Therapeutics Inc. 首席财务官。在此之前，Jackson先生于2018年4月至2022年5月担任Ra Medical Systems公司首席财务官，并于2021年8月至2022年5月担任公司秘书。2016年10月至2018年4月，他担任AltheaDx，Inc的首席财务官，该公司是一家专注于精准医疗的分子诊断公司。从2014年3月至2016年3月，Jackson先生在Celladon公司担任高级财务职位，包括首席财务官，这是一家上市的临床阶段生物技术公司。2013年4月至2014年3月，他在工业生物技术公司Sapphire Energy担任高级财务职位。Jackson先生于2006年12月从圣迭戈州立大学获得金融硕士学位，1992年6月从明尼苏达大学获得会计学学士学位。Jackson先生也是一名注册会计师（非在职）。
Andrew Jackson has been the Chief Financial Officer since October 30, 2023 and Corporate Secretary since October 2025. Mr. Jackson is a financial executive with over 35 years of corporate finance experience with success in publicly traded companies and venture capital backed startups. Mr. Jackson most recently served as Chief Financial Officer of Ernexa Therapeutics Inc. from May 2022 to May 2023. Prior to his position at Ernexa Therapeutics, Mr. Jackson served as the Chief Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Interim Chief Executive Officer from August 2019 to March 2020. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a molecular diagnostics company specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial positions, including Chief Financial Officer, at Celladon Corporation, a publicly traded, clinical stage biotechnology company. From April 2013 to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. He is a certified public accountant (inactive).- Andrew Jackson，自2022年5月起担任Eterna Therapeutics Inc. 首席财务官。在此之前，Jackson先生于2018年4月至2022年5月担任Ra Medical Systems公司首席财务官，并于2021年8月至2022年5月担任公司秘书。2016年10月至2018年4月，他担任AltheaDx，Inc的首席财务官，该公司是一家专注于精准医疗的分子诊断公司。从2014年3月至2016年3月，Jackson先生在Celladon公司担任高级财务职位，包括首席财务官，这是一家上市的临床阶段生物技术公司。2013年4月至2014年3月，他在工业生物技术公司Sapphire Energy担任高级财务职位。Jackson先生于2006年12月从圣迭戈州立大学获得金融硕士学位，1992年6月从明尼苏达大学获得会计学学士学位。Jackson先生也是一名注册会计师（非在职）。
- Andrew Jackson has been the Chief Financial Officer since October 30, 2023 and Corporate Secretary since October 2025. Mr. Jackson is a financial executive with over 35 years of corporate finance experience with success in publicly traded companies and venture capital backed startups. Mr. Jackson most recently served as Chief Financial Officer of Ernexa Therapeutics Inc. from May 2022 to May 2023. Prior to his position at Ernexa Therapeutics, Mr. Jackson served as the Chief Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Interim Chief Executive Officer from August 2019 to March 2020. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a molecular diagnostics company specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial positions, including Chief Financial Officer, at Celladon Corporation, a publicly traded, clinical stage biotechnology company. From April 2013 to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. He is a certified public accountant (inactive).
- Eric Poma
Eric Poma，被任命为Calidi的首席执行官和董事，自2025年4月22日起生效。最近，Poma博士于2009年2月至2025年1月在临床阶段的生物技术公司Molecular Templates（纳斯达克股票代码：MTEM）担任首席执行官和董事会成员。2005年3月至2008年9月，Poma博士担任Innovive Pharmaceuticals业务发展副总裁。2001年至2005年，Poma博士在Imclone Systems，Inc.担任多个高级职位。2000年至2001年，Poma博士在Eagle Growth Investors，LLC担任分析师。Poma博士在北卡罗来纳大学教堂山分校获得微生物学和免疫学博士学位，在Leonard N. Stern商学院获得工商管理硕士学位，在北卡罗来纳大学教堂山分校获得生物学理学学士学位。
Eric Poma was appointed as the Chief Executive Officer and director of Calidi effective April 22, 2025. Most recently, Dr. Poma served as CEO and as a member of the board of directors at Molecular Templates (NASDAQ: MTEM), a clinical stage biotechnology company, from February 2009 until January 2025. From March 2005 to September 2008, Dr. Poma served as Vice President, Business Development of Innovive Pharmaceuticals. From 2001 to 2005, Dr. Poma held various senior level positions at Imclone Systems, Inc. From 2000 to 2001 Dr. Poma served as an analyst at Eagle Growth Investors, LLC. Dr. Poma received a Ph.D. in Microbiology and Immunology from University of North Carolina at Chapel Hill, an M.B.A. from Leonard N. Stern School of Business and a Bachelor of Science in Biology from University of North Carolina at Chapel Hill.- Eric Poma，被任命为Calidi的首席执行官和董事，自2025年4月22日起生效。最近，Poma博士于2009年2月至2025年1月在临床阶段的生物技术公司Molecular Templates（纳斯达克股票代码：MTEM）担任首席执行官和董事会成员。2005年3月至2008年9月，Poma博士担任Innovive Pharmaceuticals业务发展副总裁。2001年至2005年，Poma博士在Imclone Systems，Inc.担任多个高级职位。2000年至2001年，Poma博士在Eagle Growth Investors，LLC担任分析师。Poma博士在北卡罗来纳大学教堂山分校获得微生物学和免疫学博士学位，在Leonard N. Stern商学院获得工商管理硕士学位，在北卡罗来纳大学教堂山分校获得生物学理学学士学位。
- Eric Poma was appointed as the Chief Executive Officer and director of Calidi effective April 22, 2025. Most recently, Dr. Poma served as CEO and as a member of the board of directors at Molecular Templates (NASDAQ: MTEM), a clinical stage biotechnology company, from February 2009 until January 2025. From March 2005 to September 2008, Dr. Poma served as Vice President, Business Development of Innovive Pharmaceuticals. From 2001 to 2005, Dr. Poma held various senior level positions at Imclone Systems, Inc. From 2000 to 2001 Dr. Poma served as an analyst at Eagle Growth Investors, LLC. Dr. Poma received a Ph.D. in Microbiology and Immunology from University of North Carolina at Chapel Hill, an M.B.A. from Leonard N. Stern School of Business and a Bachelor of Science in Biology from University of North Carolina at Chapel Hill.
- Antonio F. Santidrian
Antonio F. Santidrian自2023年7月起担任首席科学官，自2025年1月起担任技术运营主管。Santidrian博士于2015年加入Calidi，担任副主任，是一位成就卓著的科学家，在抗癌转化研究方面拥有超过24年的经验。Santidrian博士的科学生涯专注于开发卓越的癌症药物和改善人类健康的生物药物。从2008年3月到2015年9月，Santidrian博士在斯克里普斯研究所领导了几种治疗乳腺癌转移的小分子和生物药物的转化研究。Santidrian博士在巴塞罗那大学（西班牙）密切合作进行转化癌症研究，以开发ACADRA治疗慢性淋巴细胞白血病（CLL）。Santidrian博士是August Pi i Sunyer基金会、科学和教育部（西班牙）和Susan G. Komen乳腺癌基金会的研究金获得者。Santidrian博士于2001年获得巴塞罗那大学药学学位，2006年获得西班牙巴塞罗那巴塞罗那大学生物医学博士学位，专门研究抗癌疗法。
Antonio F. Santidrian has been the Chief Scientific Officer since July 2023 and the Head of Technical Operations since January 2025. Dr. Santidrian joined Calidi in 2015 as Associate Director and is an accomplished scientist with over 24 years of experience in anti cancer translational research. Dr. Santidrian has focused his scientific career on developing superior cancer drugs and on biological drugs to improve human health. From March 2008 to September 2015, Dr. Santidrian led translational studies at The Scripps Research Institute for several small molecule and biologic drugs to treat breast cancer metastasis. Dr. Santidrian worked closely on translational cancer studies for the development of ACADRA to treat chronic lymphocytic leukemia (CLL) at the University of Barcelona (Spain). Dr. Santidrian is the recipient of a fellowship from the August Pi i Sunyer Foundation, the Ministry of Science and Education (Spain) and the Susan G. Komen Breast Cancer Foundation. Dr. Santidrian received a degree in Pharmacy from the University of Barcelona in 2001 and a Ph.D. in biomedicine, specializing in anti cancer therapies in 2006 from the University of Barcelona in Barcelona, Spain.- Antonio F. Santidrian自2023年7月起担任首席科学官，自2025年1月起担任技术运营主管。Santidrian博士于2015年加入Calidi，担任副主任，是一位成就卓著的科学家，在抗癌转化研究方面拥有超过24年的经验。Santidrian博士的科学生涯专注于开发卓越的癌症药物和改善人类健康的生物药物。从2008年3月到2015年9月，Santidrian博士在斯克里普斯研究所领导了几种治疗乳腺癌转移的小分子和生物药物的转化研究。Santidrian博士在巴塞罗那大学（西班牙）密切合作进行转化癌症研究，以开发ACADRA治疗慢性淋巴细胞白血病（CLL）。Santidrian博士是August Pi i Sunyer基金会、科学和教育部（西班牙）和Susan G. Komen乳腺癌基金会的研究金获得者。Santidrian博士于2001年获得巴塞罗那大学药学学位，2006年获得西班牙巴塞罗那巴塞罗那大学生物医学博士学位，专门研究抗癌疗法。
- Antonio F. Santidrian has been the Chief Scientific Officer since July 2023 and the Head of Technical Operations since January 2025. Dr. Santidrian joined Calidi in 2015 as Associate Director and is an accomplished scientist with over 24 years of experience in anti cancer translational research. Dr. Santidrian has focused his scientific career on developing superior cancer drugs and on biological drugs to improve human health. From March 2008 to September 2015, Dr. Santidrian led translational studies at The Scripps Research Institute for several small molecule and biologic drugs to treat breast cancer metastasis. Dr. Santidrian worked closely on translational cancer studies for the development of ACADRA to treat chronic lymphocytic leukemia (CLL) at the University of Barcelona (Spain). Dr. Santidrian is the recipient of a fellowship from the August Pi i Sunyer Foundation, the Ministry of Science and Education (Spain) and the Susan G. Komen Breast Cancer Foundation. Dr. Santidrian received a degree in Pharmacy from the University of Barcelona in 2001 and a Ph.D. in biomedicine, specializing in anti cancer therapies in 2006 from the University of Barcelona in Barcelona, Spain.